Other formats:
BibTeX
LaTeX
RIS
@article{1834752,
author = {Bílek, Ondřej and Holánek, Miloš and Juřica, Jan and Stepankova, Sona and Vasina, Jiri and Selingerová, Iveta and Poprach, Alexandr and Bořilová, Simona and Kazda, Tomáš and Kiss, Igor and Zdražilová Dubská, Lenka},
article_location = {AMSTERDAM},
article_number = {October 2021},
doi = {http://dx.doi.org/10.1016/j.intimp.2021.108012},
keywords = {ALK plus NSCLC; Kidney transplant; Alectinib; Crizotinib; cyclosporine A; Drug interaction},
language = {eng},
issn = {1567-5769},
journal = {International Immunopharmacology},
title = {Drug interaction profile of TKI alectinib allows effective and safe treatment of ALK plus lung cancer in the kidney transplant recipient},
url = {https://www.sciencedirect.com/science/article/pii/S1567576921006482?via%3Dihub},
volume = {99},
year = {2021}
}
TY - JOUR
ID - 1834752
AU - Bílek, Ondřej - Holánek, Miloš - Juřica, Jan - Stepankova, Sona - Vasina, Jiri - Selingerová, Iveta - Poprach, Alexandr - Bořilová, Simona - Kazda, Tomáš - Kiss, Igor - Zdražilová Dubská, Lenka
PY - 2021
TI - Drug interaction profile of TKI alectinib allows effective and safe treatment of ALK plus lung cancer in the kidney transplant recipient
JF - International Immunopharmacology
VL - 99
IS - October 2021
SP - 1-6
EP - 1-6
PB - ELSEVIER
SN - 15675769
KW - ALK plus NSCLC
KW - Kidney transplant
KW - Alectinib
KW - Crizotinib
KW - cyclosporine A
KW - Drug interaction
UR - https://www.sciencedirect.com/science/article/pii/S1567576921006482?via%3Dihub
N2 - ALK targeting with tyrosine kinase inhibitors (TKIs) is a highly potent treatment option for the therapy of ALK positive non-small cell lung cancer (NSCLC). However, pharmacokinetics of TKIs leads to clinically significant drug interactions, and the interfering co-medication may hamper the anti-cancer therapeutic management. Here, we present for the first time a drug interaction profile of ALK-TKIs, crizotinib and alectinib, and immunosuppressive agent cyclosporine A in kidney transplant recipients diagnosed with ALK+ lung cancer. Based on therapeutic drug monitoring of cyclosporin A plasma level, the dose of cyclosporine A has been adjusted to achieve a safe and effective therapeutic level in terms of both cancer treatment and kidney transplant condition. Particularly, 15 years upon the kidney transplantation, the stage IV lung cancer patient was treated with the 1st-line chemotherapy, the 2nd-line ALK-TKI crizotinib followed by ALK-TKI alectinib. The successful therapy with ALK-TKIs has been continuing for more than 36 months, including the period when the patient was treated for COVID-19 bilateral pneumonia. Hence, the therapy of ALK+ NSCLC with ALK-TKIs in organ transplant recipients treated with cyclosporine A may be feasible and effective.
ER -
BÍLEK, Ondřej, Miloš HOLÁNEK, Jan JUŘICA, Sona STEPANKOVA, Jiri VASINA, Iveta SELINGEROVÁ, Alexandr POPRACH, Simona BOŘILOVÁ, Tomáš KAZDA, Igor KISS and Lenka ZDRAŽILOVÁ DUBSKÁ. Drug interaction profile of TKI alectinib allows effective and safe treatment of ALK plus lung cancer in the kidney transplant recipient. \textit{International Immunopharmacology}. AMSTERDAM: ELSEVIER, 2021, vol.~99, October 2021, p.~1-6. ISSN~1567-5769. Available from: https://dx.doi.org/10.1016/j.intimp.2021.108012.
|
